NEW YORK – C2N Diagnostics and Unilabs announced on Wednesday an agreement to make C2N's Precivity Alzheimer's blood tests available in Europe and other geographies.
Under the multiyear, exclusive agreement, Unilabs will offer the Precivity test on an exclusive basis in European countries including Norway, Switzerland, and the United Kingdom as well as countries outside Europe including Peru, Saudi Arabia, and the United Arab Emirates.
The partners will facilitate a technology transfer of St. Louis-based C2N's Alzheimer's blood biomarkers to a Unilabs testing network across Europe.
Financial and other terms of the agreement were not disclosed.
In a recent study in the Journal of the American Medical Association, C2N's PrecivityAD2 test showed more than 90 percent accuracy in diagnosing Alzheimer's disease. Blood tests for Alzheimer's have the potential to streamline diagnosis of the condition as they are less expensive and less invasive than existing approaches like cerebrospinal fluid testing and PET imaging.
"C2N’s Precivity portfolio of blood tests and its innovative biomarker pipeline offer the highest performance precision tools in the industry," Unilabs Head of Innovation Rahul Chaudhary said in a statement. "We expect these innovations to appeal to healthcare providers in Europe, the Gulf Region, and Latin America who rely on us, and to our biopharma collaborators who are developing new therapies."
"The sobering impact of Alzheimer’s disease reaches beyond any one country’s borders, and that’s why it’s vital we respond to the global interest in our Precivity blood tests," C2N CEO Joel Braunstein said in a statement. "We believe this collaboration allows for the acceleration of equitable access to the highest quality blood biomarkers that can aid in the diagnosis of Alzheimer’s disease."